

## P21 raises €10 million

**P**21 GmbH, a developer of fuel cell systems for mobile operators, recently announced a 10 million euro financing round. Yellow&Blue Investment Management, a venture capital firm specializing in clean energy investments, led the financing round together with P21 management and existing investors Target Partners and Conduit Ventures. P21 was established in 2001 through a management buy-out from Vodafone and currently provides the hydrogen-powered PEM fuel cell system to mobile operators and equipment suppliers to assure uninterrupted electrical power supply for telecom towers and base stations. P21 operates in the Middle East & Africa, Asia and Europe where it is implementing its solutions that optimize the use of diesel generator, fuel cell systems and renewable energy sources such as solar and wind. Wolfgang Essig, CEO of P21: "We are excited to have Yellow&Blue as a new shareholder and are keen to leverage their experience building international operations. By lowering costs and effectively integrating renewables we have created strong demand for our energy management solutions. This funding will help accelerate commercial rollout with key customers in our target markets." Dr. Albert Fischer, Managing Director of Yellow&Blue: "I have been impressed by the team and their understanding of local level energy needs. P21 energy solutions are helping mobile network operators cut costs, increase renewable energy use and reduce greenhouse gas emissions." **ACQ**

## PlexPress receives a \$2.75m investment

**P**lexPress has announced the closure of 2.75M USD seed funding from venture capital investors for introducing a game changing gene expression analysis solution to advance biological science, drug discovery, plant sciences and diagnostics. The investors include Conor Technology Fund I, Veraventure, Helsinki University Fund and VTT. Mr. Matti Copeland, Chairman of the Board of PlexPress states, "This investment provides funds for PlexPress to commercialize TRAC technology to help enable the next frontier of gene function analysis, namely, a better understanding of the mechanisms of biological systems." TRAC (Transcription analysis with Affinity Capture) was invented at VTT by prof. Hans Söderlund, one of the founders of the spinout company. It is a novel, well vetted method to measure expression of many genes (2-150) in many samples (hundreds to thousands), an underserved portion of a market growing to \$1B/yr in four years. The high information content provided by TRAC helps researchers make evidenced-based decisions. PlexPress' patented technology dramatically simplifies researchers' work practices while enabling superior precision, greater flexibility and lower cost. Further, diagnostic opportunities will substantially contribute to PlexPress' long term growth. Mr. Robert Dunkle, CEO of PlexPress Inc. states, "TRAC has proven to be very compelling in biological pathway analysis, disease characterization, cell signaling and other key application areas. Pre-launch customers have identified new targets and biomarkers for drugs through analysis of the high information content provided by TRAC. One customer stated TRAC's flexible configuration allows for multiple dimensional experimental designs not practical using other methods and not contemplated prior to TRAC." **ACQ**

## ProtAffin Second Round of funding

**A**tlas Venture and GlaxoSmithKline corporate venture fund SR One have co-led a €14.1m second round of funding for Austrian biotech business ProtAffin. Existing investors Aescap Venture, Entrepreneurs Fund and Z-Cube also participated in the round.

WOLF THEISS has a long-standing working relationship with the Company. WOLF THEISS assisted in founding the Company in 2005. Since the foundation of the Company WOLF THEISS acted as legal counsel in various matters (i.e. capital increases with the minority shareholders and in the course of the Series A Financing, preparation of a Stock Option Plan for the Company and providing legal support referring to the granting of stock options to e.g. the management board and various employees of the Company, providing legal support for shareholders' meetings, assessment of various contracts etc). Christian Hoenig, equity partner with WOLF THEISS Rechtsanwältin GmbH ("WOLF THEISS"), and Marion Loinger, associate with WOLF THEISS, led the team.

The deal marked Management Factory's first assignment with ATLAS, after getting in contact via a portfolio company, which is a client of Management Factory. Dr. Georg Zachhuber, Principal with Management Factory led the team, he commented: "Management Factory Corporate Advisory GmbH focuses on consulting for CFOs and investors as well as on interim management in finance roles ("rent-a-CFO"). Our extensive expertise in M&A processes and in biotech allowed us to conduct the ProtAffin Financial Due Diligence efficiently within a tight timeline. We also advised Sandoz on the spin-off of Nabriva and its initial round of funding. Currently, we are engaged as rent-a-CFO for a biotech company." **ACQ**

*This announcement appears as a matter of record only*

### P21 Raises €10 Million

Legal Advisor to Yellow&Blue:



Legal Advisor to P21:



*This announcement appears as a matter of record only*

### PlexPress \$2.75 Million Seed Funding

Debt Provider:



Legal Advisor to PlexPress:



*This announcement appears as a matter of record only*

### ProtAffin Second Round of Funding

Legal Adviser to the Company:



Financial Due Diligence Provider:



Legal Adviser to the Equity Providers:



Tax Adviser:

